ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

DEPO: Depomed Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

DEPOMED INC (NASD)
DEPO	3.30	N/A	(N/A%)	Vol. 0	N/A ET

Depomed, Inc. is a specialty pharmaceutical company utilizing its innovative AcuForm drug delivery technology to develop novel oral products and improved, extended release formulations of existing oral drugs. AcuForm-based products are designed to provide once- daily administration and reduced side effects, improving patient convenience, compliance and pharmacokinetic profiles. ProQuin XR extended-release tablets have been approved by the FDA for the once-daily treatment of uncomplicated urinary tract infections and are currently being marketed in the United States. In addition, once-daily Glumetza has been approved for use in adults with type two diabetes and is currently being marketed in the United States and Canada. The company is currently evaluating Gabapentin GR for the treatment of two pain indications, postherpetic neuralgia and diabetic peripheral neuropathy, and menopausal hot flashes.

General Information

DEPOMED INC

1360 O???Brien Drive Menlo Park, CA 94025 Phone: 650 462-5900 Fax: 650-513-0999 Web: www.depomedinc.com Email: investors@depomedinc.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/04/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	3.30
52 Week High	6.40
52 Week Low	1.37
Beta	1.57
20 Day Moving Average	495,838.25
Target Price Consensus	7.75

% Price Change
4 Week	-0.30
12 Week	6.45
YTD	100.00

% Price Change Relative to S&P 500
4 Week	-1.38
12 Week	0.36
YTD	65.52

Share Information
Shares Outstanding (millions)	51.61
Market Capitalization (millions)	170.31
Short Ratio	1.36
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.13
Current Year EPS Consensus Estimate	-0.49
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/04/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	16.67%
vs. Previous Quarter	47.37%

Sales Growth
vs. Previous Year	63.09%
vs. Previous Quarter:	98.26%

Price Ratios
Price/Book	9.40
Price/Cash Flow	-
Price / Sales	3.23

ROE
09/30/09	-161.35
06/30/09	-141.91
03/31/09	-95.07

ROA
09/30/09	-36.88
06/30/09	-37.37
03/31/09	-29.75

Current Ratio
09/30/09	2.43
06/30/09	2.77
03/31/09	3.25

Quick Ratio
09/30/09	2.37
06/30/09	2.69
03/31/09	3.14

Operating Margin
09/30/09	-68.78
06/30/09	-83.56
03/31/09	-73.69

Net Margin
09/30/09	-56.29
06/30/09	-71.43
03/31/09	-47.23

Pre-Tax Margin
09/30/09	-56.29
06/30/09	-71.43
03/31/09	-47.23

Book Value
09/30/09	0.35
06/30/09	0.29
03/31/09	0.46

Inventory Turnover
09/30/09	1.88
06/30/09	2.11
03/31/09	1.82

Debt-to-Equity
09/30/09	0.17
06/30/09	0.27
03/31/09	0.21

Debt to Capital
09/30/09	14.78
06/30/09	21.54
03/31/09	17.51


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research